



# SoFlacs



**SEMINAR**

**"Drug Discovery Process From  
Conception to Commercialization"**

**Dr. Mukund Chorghade**

**THINQ Pharma, Natick, MA**

**Monday, November 9**

2:00 PM, Florida Memorial University  
FMC/FIU Auditorium  
15800 NW 42 Ave, Miami Gardens

and

6:30 PM, Nova Southeastern Univ.  
Health Professions Assembly Bldg.  
Morris Auditorium, Ft. Lauderdale

see: <http://www.nova.edu/locations/maps/index.html>

## **The Drug Discovery Process From Conception to Commercialization: Value Creation and New Opportunities in Medicinal Chemistry and Drug Discovery**

### **Mukund S. Chorghade\***

Chief Scientific Officer,

THINQ Pharma, 14 Carlson Circle, Natick, MA 01760-4205 USA

Tel: 1-508-651-7809, Mobile: 1-508-308-3891 Fax: 1-508-651-7920

Email: [Chorghade@comcast.net](mailto:Chorghade@comcast.net)

The pharmaceutical sector has traditionally been a vibrant, innovation-driven and highly successful component of industry at large. In recent years, a confluence of spectacular advances in chemistry, molecular biology, genomics and chemical technology and the cognate fields of spectroscopy, chromatography and crystallography has led to the discovery and development of numerous novel therapeutic agents for the treatment of a wide spectrum of diseases. In order to facilitate this process, there has been a significant and noticeable effort aimed at improving the integration of discovery technologies, chemical outsourcing for route selection / delivery of active pharmaceutical ingredients, drug product formulations, clinical trials and refined deployment of information technologies. Multi-disciplinary and multi-functional teams focusing on lead generation and optimization have replaced the traditional, specialized research groups. To develop a drug from conception to commercialization, the biotechnology / biopharmaceutical industry (which has been highly entrepreneurial) has reached out and established global strategic partnerships with numerous companies.

The pharmaceutical industry in the U.S.A. and Europe has undergone unprecedented changes in recent years primarily due to mergers and acquisitions. The rapidly increasing pace of regulatory reform allied with the necessity of effecting drastic reductions in the price of bulk drugs have also resulted in marked shifts in the strategic paradigms in this industry. The lecture provides a humorous overview of strategies, tactics, milestones and benchmarks in the entire sequence of operations involved in discovering a drug and delivering it to the armamentarium of clinicians and medical practitioners. Strategic in licensing, virtual company interactions and related topics are also included.